Xcout IntelAligos Therapeutics, Inc.
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
Subscribe to see Aligos Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Aligos Therapeutics, Inc. at a glance
Aligos Therapeutics, Inc. is a biotech company headquartered in South San Francisco, United States. It is publicly listed (ALGS) with a market capitalisation of $25.2M. Xcout tracks 34 named people at Aligos Therapeutics, Inc., including Lawrence Blatt (Chief Executive Officer, President & Chairman of the Board).
Aligos Therapeutics, Inc. leadership
- Lawrence BlattChief Executive Officer, President & Chairman of the Board
- Lawrence M. BlattPresident and Chief Executive Officer
- Lesley Ann CalhounExecutive Vice President, Chief Financial Officer & Chief Operating Officer
- Julian A. Symons DPHILExecutive Vice President & Chief Scientific Officer
- Sushmita Chanda DABTExecutive Vice President & Chief Development Officer
- David SmithExecutive Vice President & Head of Chemical Operations
28 more named people on record for Aligos Therapeutics, Inc., with roles, board committees and tenure — see the full roster →
Aligos Therapeutics, Inc. funding rounds on record
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $125M | 1 named | |
| Series A | $100M | — |
Some filings are not shown as funding rounds.
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Get Aligos Therapeutics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Aligos Therapeutics, Inc. in Xcout Intel
- 34 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- 1 corporate event with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access